Ireland· IE-PA-EU/1/18/1299/001
Yescarta 0.4 – 2 × 108 cells dispersion for infusion
A other antineoplastic agents product containing axicabtagene ciloleucel, registered in Ireland by Kite Pharma EU B.V.. The same ATC class is registered in 5 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Axicabtagene ciloleucel is registered in 5 of 19 countries.
Countries holding a registration under ATC L01X (other antineoplastic agents), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 3 of them publish a price we can compare per daily dose
Axicabtagene ciloleucel · ATC L01X
5 / 19 countries
- Belgiumprice
- Canada
- Finlandprice
- Ireland
- Switzerlandprice
The record
At a glance
HPRA (Ireland)- Active substance
- AXICABTAGENE CILOLEUCEL
- Manufacturer
- Kite Pharma EU B.V.
- Country
- Ireland (IE)
- ATC code
- L01X
- ATC class
- OTHER ANTINEOPLASTIC AGENTS
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/18/1299/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Axicabtagene ciloleucel in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesYESCARTAKite Pharma, Inc.
- CanadaYESCARTAGILEAD SCIENCES CANADA INC
- SwitzerlandYescartaGilead Sciences Switzerland Sàrl
- CzechiaYESCARTAKite Pharma EU B.V., Hoofddorp
- SpainYESCARTA 0,4 - 2 x 10e8 CELULAS DISPERSION PARA PERFUSIONKite Pharma Eu B.V.
- FinlandYescartaKite Pharma EU B.V.
- FranceYESCARTA 0,4 - 2 x 100 000 000 cellules, dispersion pour perfusionKITE PHARMA EU (PAYS-BAS)
- BelgiumYescarta 0,4–2 x 10*8 cellsKite Pharma EU
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Yescarta
- Liechtenstein · Yescarta
- Norway · Yescarta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e97fb58b-07d5-4e23-a399-c1d363af7872 GET /v1/drugs/e97fb58b-07d5-4e23-a399-c1d363af7872?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Dispersion for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"L01X"
],
"strength": null,
"pa_number": "EU/1/18/1299/001",
"substances": [
"AXICABTAGENE CILOLEUCEL"
],
"legal_basis": "New active substance (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "23/08/2018",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about axicabtagene ciloleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.